Trainer Rx selects healthcare veteran Mark Olson as its CEO

WALNUT Creek, Calif., July 17, 2018 — Thirty-year healthcare veteran Mark Luck Olson has recently joined Trainer Rx as its new CEO and will drive the company’s accelerated growth into new markets.

“Mark Olson has an impressive track record of growing companies from the ground up,” said Michael Oberlander, MD, the company’s founder and chief medical officer. “His expertise in the health services market, particularly in the health plans and delivery systems, will serve the company well as we look to expand our service offerings. We’re truly fortunate to have him on our team.”

Trainer Rx is one of the fastest growing telerehab platforms in the market and is now poised to expand its footprint globally. Trainer Rx found Olson through its investment partner 
7wire Ventures.

“7wire Ventures believes in the philosophy that value comes from connecting ideas and talent with the right company,” noted Robert Garber, partner at 7wire Ventures. “Mark Olson has built a reputation as a health tech strategist who can unleash an organization’s potential. We believe he will amplify the growth Trainer Rx is already experiencing.”

“Musculoskeletal conditions afflict one in three adults each year and cost nearly $1 billion dollars in the U.S. alone,” said Olson. “Trainer Rx delivers the health value trifecta: better and faster recovery from orthopedic injuries, lower medical costs and a vastly superior consumer experience. Along the way, Trainer Rx targets the fundamental drivers of pain, reducing unwarranted use of opioids. I believe Trainer Rx can play a meaningful role in fighting the crisis of opiate addiction. I’m excited to be a part of this group.”

Olson previously lead Global Services for Decision Resources Group as its president, organically growing the custom services business by 69 percent in four years. He also served as a managing partner of ChapterHouse, LLC, a strategic consultancy serving payers and providers prior to its acquisition by Oliver Wyman, a subsidiary of the Marsh & McLennan Companies. After the acquisition, Olson served as managing partner in Oliver Wyman’s Health and Life Sciences practice.

Olson also spent nearly a decade at Baxter Healthcare, a leading global medical device and tech company. There, he drove and executed the strategic growth plans for Baxter in Europe and the Far East, eventually becoming chief information officer for Baxter’s $2 billion global biotech business. Olson received both his undergraduate and master’s degrees in business from the Massachusetts Institute of Technology at Cambridge.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”